Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy

Fernando M. Penha, Giovanni Gregori, Carlos Alexandre De Amorim Garcia Filho, Zohar Yehoshua, William J Feuer, Philip J Rosenfeld

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: To determine if quantitative changes in retinal pigment epithelial detachments (PEDs) predict the need for retreatment in eyes undergoing spectral domain optical coherence tomography (SD OCT)-guided as-needed therapy with anti-vascular endothelial growth factor drugs. METHODS:: Patients with vascularized PEDs undergoing SD OCT-guided treatment with anti-vascular endothelial growth factor drugs were retrospectively identified. The decision to retreat these cases was based on qualitative assessments of fluid in the macula. Spectral domain OCT images from visits in which the treatment was withheld were retrospectively analyzed. A novel algorithm was then used to measure the area and volume of PEDs at these visits. RESULTS:: Fourteen eyes were identified, and retreatment was withheld at 57 visits. When the SD OCT algorithm was used to evaluate the scans from these visits, the PED volume increased at eight visits. At all of these eight visits, a treatment was needed at the next follow-up visit. For the remaining 49 visits in which the treatment was withheld, the PED volume did not increase and no treatment was needed at the next follow-up visit. CONCLUSION:: Quantitation of the change in the PED volume and area may be useful in determining when to retreat eyes undergoing SD OCT-guided as-needed anti-vascular endothelial growth factor therapy.

Original languageEnglish
Pages (from-to)459-466
Number of pages8
JournalRetina
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2013

Fingerprint

Retreatment
Retinal Detachment
Vascular Endothelial Growth Factor A
Optical Coherence Tomography
Therapeutics
Pharmaceutical Preparations

Keywords

  • aflibercept
  • age-related macular degeneration
  • anti-VEGF
  • bevacizumab
  • optical coherence tomography
  • pigment epithelium detachment
  • ranibizumab
  • spectral domain

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. / Penha, Fernando M.; Gregori, Giovanni; Garcia Filho, Carlos Alexandre De Amorim; Yehoshua, Zohar; Feuer, William J; Rosenfeld, Philip J.

In: Retina, Vol. 33, No. 3, 01.03.2013, p. 459-466.

Research output: Contribution to journalArticle

Penha, Fernando M. ; Gregori, Giovanni ; Garcia Filho, Carlos Alexandre De Amorim ; Yehoshua, Zohar ; Feuer, William J ; Rosenfeld, Philip J. / Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy. In: Retina. 2013 ; Vol. 33, No. 3. pp. 459-466.
@article{15e37a5321364defa2d759c14f12ae2b,
title = "Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy",
abstract = "Purpose: To determine if quantitative changes in retinal pigment epithelial detachments (PEDs) predict the need for retreatment in eyes undergoing spectral domain optical coherence tomography (SD OCT)-guided as-needed therapy with anti-vascular endothelial growth factor drugs. METHODS:: Patients with vascularized PEDs undergoing SD OCT-guided treatment with anti-vascular endothelial growth factor drugs were retrospectively identified. The decision to retreat these cases was based on qualitative assessments of fluid in the macula. Spectral domain OCT images from visits in which the treatment was withheld were retrospectively analyzed. A novel algorithm was then used to measure the area and volume of PEDs at these visits. RESULTS:: Fourteen eyes were identified, and retreatment was withheld at 57 visits. When the SD OCT algorithm was used to evaluate the scans from these visits, the PED volume increased at eight visits. At all of these eight visits, a treatment was needed at the next follow-up visit. For the remaining 49 visits in which the treatment was withheld, the PED volume did not increase and no treatment was needed at the next follow-up visit. CONCLUSION:: Quantitation of the change in the PED volume and area may be useful in determining when to retreat eyes undergoing SD OCT-guided as-needed anti-vascular endothelial growth factor therapy.",
keywords = "aflibercept, age-related macular degeneration, anti-VEGF, bevacizumab, optical coherence tomography, pigment epithelium detachment, ranibizumab, spectral domain",
author = "Penha, {Fernando M.} and Giovanni Gregori and {Garcia Filho}, {Carlos Alexandre De Amorim} and Zohar Yehoshua and Feuer, {William J} and Rosenfeld, {Philip J}",
year = "2013",
month = "3",
day = "1",
doi = "10.1097/IAE.0b013e31827d2657",
language = "English",
volume = "33",
pages = "459--466",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy

AU - Penha, Fernando M.

AU - Gregori, Giovanni

AU - Garcia Filho, Carlos Alexandre De Amorim

AU - Yehoshua, Zohar

AU - Feuer, William J

AU - Rosenfeld, Philip J

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose: To determine if quantitative changes in retinal pigment epithelial detachments (PEDs) predict the need for retreatment in eyes undergoing spectral domain optical coherence tomography (SD OCT)-guided as-needed therapy with anti-vascular endothelial growth factor drugs. METHODS:: Patients with vascularized PEDs undergoing SD OCT-guided treatment with anti-vascular endothelial growth factor drugs were retrospectively identified. The decision to retreat these cases was based on qualitative assessments of fluid in the macula. Spectral domain OCT images from visits in which the treatment was withheld were retrospectively analyzed. A novel algorithm was then used to measure the area and volume of PEDs at these visits. RESULTS:: Fourteen eyes were identified, and retreatment was withheld at 57 visits. When the SD OCT algorithm was used to evaluate the scans from these visits, the PED volume increased at eight visits. At all of these eight visits, a treatment was needed at the next follow-up visit. For the remaining 49 visits in which the treatment was withheld, the PED volume did not increase and no treatment was needed at the next follow-up visit. CONCLUSION:: Quantitation of the change in the PED volume and area may be useful in determining when to retreat eyes undergoing SD OCT-guided as-needed anti-vascular endothelial growth factor therapy.

AB - Purpose: To determine if quantitative changes in retinal pigment epithelial detachments (PEDs) predict the need for retreatment in eyes undergoing spectral domain optical coherence tomography (SD OCT)-guided as-needed therapy with anti-vascular endothelial growth factor drugs. METHODS:: Patients with vascularized PEDs undergoing SD OCT-guided treatment with anti-vascular endothelial growth factor drugs were retrospectively identified. The decision to retreat these cases was based on qualitative assessments of fluid in the macula. Spectral domain OCT images from visits in which the treatment was withheld were retrospectively analyzed. A novel algorithm was then used to measure the area and volume of PEDs at these visits. RESULTS:: Fourteen eyes were identified, and retreatment was withheld at 57 visits. When the SD OCT algorithm was used to evaluate the scans from these visits, the PED volume increased at eight visits. At all of these eight visits, a treatment was needed at the next follow-up visit. For the remaining 49 visits in which the treatment was withheld, the PED volume did not increase and no treatment was needed at the next follow-up visit. CONCLUSION:: Quantitation of the change in the PED volume and area may be useful in determining when to retreat eyes undergoing SD OCT-guided as-needed anti-vascular endothelial growth factor therapy.

KW - aflibercept

KW - age-related macular degeneration

KW - anti-VEGF

KW - bevacizumab

KW - optical coherence tomography

KW - pigment epithelium detachment

KW - ranibizumab

KW - spectral domain

UR - http://www.scopus.com/inward/record.url?scp=84874949338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874949338&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31827d2657

DO - 10.1097/IAE.0b013e31827d2657

M3 - Article

C2 - 23400085

AN - SCOPUS:84874949338

VL - 33

SP - 459

EP - 466

JO - Retina

JF - Retina

SN - 0275-004X

IS - 3

ER -